Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

Perrigo Company Appointed Generic Distributor by Medimetriks Pharmaceuticals

By Pharmaceutical Processing | January 26, 2009

Medimetriks Pharmaceuticals announced today that the company has entered into a Distributor Agreement with Perrigo Company, a manufacturer in the generic prescription marketplace, designating Perrigo as the Exclusive Authorized Distributor of generic versions of Medimetriks’ branded products in the U.S. The agreement calls for Medimetriks to receive a percentage of Perrigo’s Net Sales on the non-branded products, allowing Medimetriks to maximize its investment in its brands and maintain a revenue stream from the markets these brands create. Founded in May, 2008, Medimetriks launched its first prescription brands in the 4th Quarter of 2008 to the Dermatology and Podiatry markets. These brands include Pacnex(TM) (7% Benzoyl Peroxide) Wash, a topical treatment for acne in a unique vehicle containing Aloe and Green Tea; Sumaxin(TM) (Sodium sulfacetamide 10% & sulfur 4 Cleansing Pads, a topical treatment for acne and rosacea also in a vehicle containing Aloe and Green Tea; and Uramaxin(TM) (45% Urea) Nail Gel, a treatment for diseased and damaged nails in a unique vehicle containing Menthol, Camphor and Eucalyptus Oil. The agreement also includes future products launched by Medimetriks. “Our agreement with Perrigo represents a strategic opportunity for Medimetriks to leverage our brand assets in the non-branded marketplace,” stated Bradley Glassman, President and CEO of Medimetriks. “We are pleased to work with one of the world’s leading healthcare manufacturers and generic marketers, with a particular expertise in the topical generic market.” “We believe our relationship with Medimetriks will be a mutually beneficial one,” stated Sharon Kochan, Executive Vice President of Perrigo. “Medimetriks’ Management Team, having previously built Bradley Pharmaceuticals into an approximately $200 million gross revenue company, has a solid track record of success in building a branded pharmaceutical business in the markets they serve.”

Related Articles Read More >

Pfizer logo
Pfizer seeks to comply with voluntary Net-Zero Standard by 2040
Fujifilm Diosynth Technologies
Fujifilm to spend $1.6B to bolster cell culture manufacturing services
Wyzo
Wyzo high-speed pick-and-place sidebot wins design awards
Purdue University
Purdue University launches institute for advanced manufacturing of pharmaceuticals

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards